Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2, BCL6, BCL5, BCL6A, LAZ3, ZBTB27, ZNF51, B-cell CLL/lymphoma 6
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
;
604
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
MYC amplification (29)
MYC amplification + HER-2 amplification (1)
BCL2 amplification (1)
MYC amplification (29)
MYC amplification + HER-2 amplification (1)
BCL2 amplification (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Lymphoma
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
lisocabtagene maraleucel
Sensitive
:
C2
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
lisocabtagene maraleucel
Sensitive
:
C2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Diffuse Large B Cell Lymphoma
acalabrutinib
Sensitive: C4 – Case Studies
acalabrutinib
Sensitive
:
C4
acalabrutinib
Sensitive: C4 – Case Studies
acalabrutinib
Sensitive
:
C4
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
Lymphoma
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login